Preclinical Oncology Services Offered By Woodland Oncology Services And SBH Sciences

Aug. 22, 2012 - PRLog -- Woodland Oncology Services, a division of Woodland Pharmaceuticals, LLC announces the initiation of aligned discovery services with SBH Sciences, Inc.  Effective immediately, Woodland Oncology Services (Worcester, MA) will offer complementary in vivo modeling to align with and extend the in vitro assay services in new molecule drug discovery currently provided by SBH Sciences of Natick, MA.  This new strategic research alliance will allow current and future customers to pursue the march toward the clinic with their research compounds by translating their SBH Sciences in vitro data into the same cell line in vivo xenograft models at Woodland.  SBH and Woodland have committed their partnership toward bringing both precision and speed to this translational science capability.  

Woodland brings expertise that spans traditional cell line efficacy studies to increasingly complex PK/PD modeling and longer term dosing to elucidate failures due to PK or resistance.  In addition, through its own efforts and collaborations with global key partners, Woodland provides primary patient tumor study capabilities to aid in the translation of preclinical cell line models to the clinic.

Michael Briggs, President of Woodland Pharmaceuticals said: “I have worked with SBH Sciences in the past on in vitro models and they have proven to be reliable, efficient and excellent partners in research. SBH not only provides a service, but thinks about and adds value to the experiment.  “Just do it right!” is the mantra of the President of SBH.  I see Woodland as a logical extension to the studies that show promising in vitro results, and existing customers of SBH Sciences will receive priority scheduling for their in vivo studies contracted with Woodland.”

Raphael Nir, President of SBH Sciences, said of the strategic alliance, “It is our privilege working with Dr. Michael Briggs and his dedicated and knowledgeable team. The most rapid and efficient path to the IND starts with the preclinical in vitro and animal model studies. SBH Sciences and Woodland Oncology Services aligned discovery capabilities provides complementary expertise that will streamline the development effort, enhance innovation and reduce development time. We are constantly expanding our services and our mutual collaboration will allow us to support our customers to reach Phase I clinical trial primarily in oncology and inflammatory disorders".

Web:
SBH Sciences: www.SBHSciences.com
Woodland Oncology Services: www.woodlandoncologyservices.com